Meta description: AI-driven medical device company Cardio Intelligence has completed the first close of its Series B round, securing strategic investment for product and market expansion.
Cardio Intelligence has confirmed the first close of its Series B funding round through a third-party allotment. The raise brings in new strategic investors to support accelerated product development and overseas market entry. This update matters to investors tracking health technology scale-ups, medtech innovators, and stakeholders watching AI-driven diagnostics adoption.
Who invested in this round?
The first tranche of the Series B round was led by Shin Nippon Biomedical Laboratories. Additional participation came from Tokai Tokyo Investment and Iwagin Business Creation Capital. The exact capital figure has not been made public. The structure was executed through a third-party allotment, signaling targeted strategic support rather than broad market placement.
What does this mean for growth?
The investment gives Cardio Intelligence resources to strengthen internal operations and advance global expansion. The leadership team is focused on improving product quality and scaling real-world deployment of existing devices. Expansion to overseas markets is a stated priority, aligning with a vision to enhance workflow efficiency in healthcare and enable earlier cardiac arrhythmia diagnostics.
Given the company’s track record since its founding in 2019, investors may interpret this round as a growth-stage inflection point. With its AI-based electrocardiogram analysis technology already adopted by more than 150 medical institutions, the firm has established baseline market trust that can be leveraged in entry to new geographies.
How is the funding allocated?
Management plans to direct proceeds into several areas:
- Development of new AI-driven medical device software
- Strengthening operational capabilities and internal teams
- International market preparation and expansion
Recent product milestones contextualize this allocation. In February 2022, the company commercialized the SmartRobin AI Series for long-term electrocardiogram analysis. In late 2024, it received approvals for SmartPAFin software aimed at detection of paroxysmal atrial fibrillation. September 2024 also saw the start of development for a heart failure severity evaluation tool using voice analysis. Both ECG and voice analytics form the core technological base, which the new funding will deepen.
FAQ
1. What stage is Cardio Intelligence at?
Cardio Intelligence is in a growth stage, scaling existing products and developing new ones while preparing for international markets.
2. Who are the lead and participating investors?
Shin Nippon Biomedical Laboratories is the lead investor. Tokai Tokyo Investment and Iwagin Business Creation Capital joined the round.
3. Is the total amount of funding disclosed?
No. The company has not announced the specific raise amount for this first tranche.
4. What regulatory milestones has the company achieved?
It has secured approval for its SmartPAFin atrial fibrillation detection software and launched the SmartRobin AI Series in medical institutions.
Conclusion
Cardio Intelligence’s Series B first close brings in targeted capital from experienced biomedical and investment players. The strategic focus on new product launches, quality improvement, and overseas expansion suggests an acceleration of its integrated cardiac diagnostic solutions. For founders and investors, the case illustrates how regulatory milestones and product adoption can position AI medtech firms for global scaling.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Readers should perform their own due diligence before making investment decisions.